Cytoplasmic p53 contributes to the removal of uracils misincorporated by HIV-1 reverse transcriptase. 2018

Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
Infectious Diseases Unit, Sheba Medical Center, Tel-Hashomer 5265601, Israel.

HIV-1 reverse transcriptase (RT) in the cytoplasm of HIV-infected cells efficiently inserts the non-canonical dUTP into the proviral DNA, and extends the dU-terminated DNA. The misincorporation of dUTP leads to mutagenesis, and uracils can down-regulate viral gene expression. However, uracilation might also protect HIV DNA from auto-integration in the cytoplasm. Tumor suppressor p53 protein, exhibiting inherent 3'→5' exonuclease activity, provides a potential host-derived repair mechanism during HIV reverse transcription for the misincorporation of various wrong nucleotides, leading to both base-base mismatches and incorporated non-canonical ribonucleotides. Since the presence of proofreading activity is essential for DNA synthesis accuracy, we elucidated the potential involvement of cytoplasmic p53 in the U-editing activities during insertion of dUTP into DNA by recombinant HIV-1 RT (using isogenic p53-proficient and -deficient HCT116 cells). The biochemical data show that p53 in cytoplasm can participate through the intermolecular pathway in a dU-damage-associated repair mechanism by its ability to remove preformed 3'-terminal dUs, thus preventing further extension of 3' dU-terminated primer during DNA synthesis by HIV-1 RT. The specific depletion of p53 from cytoplasmic lysates of repair-proficient p53-harboring cells reduced this negative effect. Accordingly, the increased abundance of p53 in nutlin-treated cells correlates with enhanced error-correction functions, namely, removal of incorporated uracil. The data substantiate the significance of p53 as a potential proofreader for removal of non-canonical dUTP from HIV DNA, thus preventing the consequences of dUTP misincorporation in cell-type specific infectivity of HIV.

UI MeSH Term Description Entries
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004260 DNA Repair The removal of DNA LESIONS and/or restoration of intact DNA strands without BASE PAIR MISMATCHES, intrastrand or interstrand crosslinks, or discontinuities in the DNA sugar-phosphate backbones. DNA Damage Response
D004261 DNA Replication The process by which a DNA molecule is duplicated. Autonomous Replication,Replication, Autonomous,Autonomous Replications,DNA Replications,Replication, DNA,Replications, Autonomous,Replications, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
March 2013, Bioorganic & medicinal chemistry,
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
January 1995, Virology,
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
June 2007, Applied microbiology and biotechnology,
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
May 2002, Biochemistry,
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
November 1988, Science (New York, N.Y.),
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
January 2008, Advances in pharmacology (San Diego, Calif.),
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
January 2000, Advances in pharmacology (San Diego, Calif.),
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
October 2004, Current HIV research,
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
July 2002, Antimicrobial agents and chemotherapy,
Yossi Saragani, and Amnon Hizi, and Galia Rahav, and Sara Zaouch, and Mary Bakhanashvili
January 1996, Biochemistry,
Copied contents to your clipboard!